Eyewire+

🌟 Bryn Mawr Communications is Attending AAO 2025! 🌟 BMC is heading to Orlando for the American Academy of Ophthalmology annual meeting, and we can’t wait to connect with you! 📍 Booth #1610 📅 October 17–20, 2025 Stop by to meet our team and experience how BMC continues to elevate eye care education and engagement. We’ll be hosting events, recording exclusive KOL insights, and showcasing the latest innovations across our platforms. #AAO2025 #Ophthalmology #EyeCareInnovation

EssilorLuxottica announced it is acquiring Ikerian AG, a Swiss health technology company operating under the RetinAI brand: https://ow.ly/Ib5x50XczSa

Dr. Uday Devgan shares his experience performing the world’s first robotic cataract surgery; Konan Medical receives CE Mark for its objectiveFIELD Analyzer perimetry device; and Biotech Healthcare launches a new full visual range EDOF IOL. Don’t miss the newest edition of EyewireTV here: https://ow.ly/Pwrq50Xc63L

OcuSciences has received CE Mark clearance for its OcuMet Beacon, a diagnostic instrument designed to enhance clinicians’ ability to assess eye health and detect retinal disorders. The CE mark signifies that the OcuMet Beacon meets the health, safety, and environmental protection standards required for commercialization across the European Economic Area (EEA): https://ow.ly/oRFZ50XbLYQ

BVI announced that the FDA has approved its Finevision HP trifocal IOL. According to BVI, Finevision HP was the world’s first trifocal IOL, with more than 15 years of clinical success and millions of implantations worldwide: https://ow.ly/w1sW50Xb7PV

This Week on Eyewire+ | Trending Stories in Vision 🔹 FDA Greenlight: Rayner secures FDA approval for the RayOne EMV Toric IOL following a pivotal IDE study. 🔹 Regulatory Milestone: Konan Medical’s objectiveFIELD Analyzer (OFA) receives CE Marking under the EU MDR, paving the way for broader European adoption of its next-generation perimetry technology. 🔹 Vision Research in Orbit: Oculus’ Smartfield perimeter launches aboard the International Space Station to support research on Spaceflight Associated Neuro-ocular Syndrome (SANS), a condition impacting astronauts’ vision on long-duration missions. Also trending on Eyewire+: 💠 EyewireTV | 10.08.2025: A first-of-its-kind presbyopia drop enters the market, Lumibird unveils ICL Guru integration, and leading gene therapy developers share clinical progress. 💠 Podcasts: Join leading surgeons as they explore lens selection strategies, AI’s role in clinical decision-making, and the economics shaping PRP practice patterns. 💠 Subspecialty Highlights: From Alcon’s latest AAO data and pre-myopia insights to novel glaucoma surgeries and telemonitoring advances—discover the developments redefining cataract, refractive, glaucoma, retina, and optometry care. Stay informed and inspired—read the full edition now on Eyewire+.

The FDA has approved Rayner's RayOne EMV Toric IOL following the completion of a pivotal investigational device exemption (IDE) study. According to Rayner, the RayOne EMV Toric lens has been engineered to provide exceptional rotational stability and refractive precision. It expands Rayner’s EMV platform, which was developed in collaboration with ophthalmic surgeon Professor Graham Barrett: https://ow.ly/UqQ350XaC6o

A first-of-its-kind presbyopia eye drop is now commercially available; Lumibird introduces ICL Guru Integration on its ultrasound platform; and the makers of gene therapy candidates for retinal diseases provide clinical updates: https://ow.ly/PjrE50X9uEq

AviadoBio and UgeneX Therapeutics Co., Ltd. announced an exclusive option and license agreement for the development and commercialization of UGX-202, an investigational AAV-based gene therapy currently in clinical development for retinitis pigmentosa (RP). The agreement also includes a second undisclosed indication expected to enter the clinic by year-end: https://ow.ly/gT1550X9kj0

In today’s Visionary Breakthroughs spotlight, Shawn O’Neil, CEO, ViaLase, Inc, discussed the company’s FLIGHT procedure, a novel, incision-free approach to glaucoma treatment that creates precisely placed apertures in the trabecular meshwork to reestablish fluid outflow from the anterior chamber to Schlemm’s canal: https://ow.ly/H6fV50X5OxL